Cozaar Paragraph IV Certification
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA's Feb. 2 updated list of first-time Paragraph IV certifications reflects a filing for Merck's angiotensin II inhibitor Cozaar (losartan)